<main class="detailed-guide" lang="en" role="main">
      



<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

<div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-l">
    Medicines: Marketing Authorisation Holders' submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
        <p class="gem-c-lead-paragraph">Marketing Authorisation Holders should review their manufacturing processes to identify and, if found, to mitigate the risk of nitrosamine impurities being present.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
      <div class="gem-c-metadata govuk-!-margin-bottom-3" data-module="gem-toggle metadata">
  <dl data-module="gem-track-click">
      <dt class="gem-c-metadata__term">From:</dt>
      <dd class="gem-c-metadata__definition">
          <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>

      </dd>
      <dt class="gem-c-metadata__term">Published</dt>
      <dd class="gem-c-metadata__definition">18 December 2019</dd>
      <dt class="gem-c-metadata__term">Last updated</dt>
      <dd class="gem-c-metadata__definition">
        11 August 2022
          — <a class="gem-c-metadata__definition-link govuk-!-display-none-print js-see-all-updates-link" data-track-action="see-all-updates-link-clicked" data-track-category="content-history" data-track-label="history" href="#full-publication-update-history">
            See all updates
          </a>
      </dd>
  </dl>
</div>
    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>

<div class="govuk-!-display-none-print govuk-!-margin-bottom-6" data-module="gem-track-click">
  <form action="/email/subscriptions/single-page/new" class="gem-c-single-page-notification-button" data-button-location="top" data-track-action="Subscribe-button-top" data-track-category="Single-page-notification-button" data-track-label="/guidance/medicines-marketing-authorisation-holders-submission-of-nitrosamine-risk-evaluation" method="POST">
    <input name="base_path" type="hidden" value="/guidance/medicines-marketing-authorisation-holders-submission-of-nitrosamine-risk-evaluation">
    <button class="govuk-body-s gem-c-single-page-notification-button__submit" type="submit">  <svg class="gem-c-single-page-notification-button__icon" height="18" viewBox="0 0 459.334 459.334" width="18" xmlns="http://www.w3.org/2000/svg"><path d="M177.216 404.514c-.001.12-.009.239-.009.359 0 30.078 24.383 54.461 54.461 54.461s54.461-24.383 54.461-54.461c0-.12-.008-.239-.009-.359H175.216zM403.549 336.438l-49.015-72.002v-89.83c0-60.581-43.144-111.079-100.381-122.459V24.485C254.152 10.963 243.19 0 229.667 0s-24.485 10.963-24.485 24.485v27.663c-57.237 11.381-100.381 61.879-100.381 122.459v89.83l-49.015 72.002a24.76 24.76 0 0 0 20.468 38.693H383.08a24.761 24.761 0 0 0 20.469-38.694z" fill="currentColor"></path></svg>Get emails about this page
</button>
</form>
</div>





<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    


      <div class="app-c-contents-list-with-body">
    
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>

        
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
          <div class="govspeak">
<h2>Overview</h2>

<p>In accordance with the <a class="govuk-link" href="https://www.ema.europa.eu/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf" rel="external">CHMP opinion under Article 5 (3) of Regulation (EC) No. 726/2004 on the presence of nitrosamine impurities in human medicinal products</a>, as a precaution, MAHs should review their manufacturing processes to identify and, if found, to mitigate the risk of nitrosamine impurities being present.</p>

<p>MAHs should work with manufacturers of API and finished products in order to review the API and finished product manufacturing processes in light of the arrangements for preventing nitrosamine formation as well as contamination or cross-contamination. This should take into account their knowledge of the manufacturing processes as well as the potential sources of nitrosamine impurities.</p>

<p>Update August 2022: Please note change to Step 3 timelines below.</p>

<h3>Deadline and inclusion of biological medicinal products</h3>

<p>The scope of the review has been widened to cover all medicinal products for human use. For example, it includes medicinal products containing chemically synthesised active pharmaceutical ingredients, as well as biological medicinal products) authorised in the UK, Great Britain (England, Scotland and Wales) and Northern Ireland.</p>

<p>The following deadlines are applicable:</p>

<h4>Step 1</h4>

<ul>
  <li>Chemical medicinal products: 31 March 2021</li>
  <li>Biological medicinal products: 1 July 2021</li>
</ul>

<h4>Step 2</h4>

<ul>
  <li>Chemical medicinal products: 26 September 2022</li>
  <li>Biological medicinal products: 1 July 2023</li>
</ul>

<h4>Step 3</h4>

<ul>
  <li>Chemical medicinal products: 1 October 2023</li>
  <li>Biological medicinal products: 1 July 2023</li>
</ul>

<p>The deadline for the submission of Step 1 risk evaluation outcomes for medicines containing chemically synthesised API has now passed.</p>

<p>MAHs that have not submitted the Step 1 risk evaluation outcomes for these medicines are reminded to comply with the conclusions of the CHMP (EMA Committee for Medicinal Products for Human Use) Scientific Opinion and provide a Step 1 submission as a matter of priority.</p>

<p>Step 1 risk evaluation outcomes must be provided for all products within the scope of the review irrespective of their marketing status.</p>

<p>The Step 3 deadline has been extended to 1 October 2023 for chemical medicinal products to enable companies to perform a thorough investigation and to establish any required risk mitigating actions in light of new scientific developments since 2020, in particular those concerning active substance-derived nitrosamines. This extension does not affect the deadline for completing the Step 2 confirmatory testing for chemical medicines, which remains 26 September 2022. Marketing authorisation holders should submit complete Step 2 outcomes by this deadline.</p>

<h3>Article 5(3) Submission of Nitrosamine risk evaluation</h3>

<h3>Step 1 - Risk Evaluation</h3>

<p>The following guidance is for all UK, Great Britain and Northern Ireland MAHs and should be followed to submit the outcomes of the Stage 1 nitrosamine risk evaluation, as detailed in the guidance CMDh practical guidance for MAHs of nationally authorised products in relation to the Art. 5(3) Referral on Nitrosamines.</p>

<p>Step 1 risk evaluation outcomes must be provided for all products within the scope of the review irrespective of their marketing status.</p>

<p>Please refer to <a class="govuk-link" href="https://www.hma.eu/620.html" rel="external">Information on Nitrosamines for Marketing Authorisation Holders</a></p>

<p>For all products licensed in the UK, Great Britain and Northern Ireland (including UK National licences and EU licences where UK is RMS or CMS), MAH should submit one of two templates supplied by CMDh depending on the risk evaluation outcome:</p>

<ul>
  <li>
    <p>Step 1 no risk identified response <a class="govuk-link" href="https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Advice_from_CMDh/Nitrosamins/CMDh_406_2019_Rev1_2021_01-_Step_1_no_risk_identified_response_template.docx" rel="external">template document</a></p>
  </li>
  <li>
    <p>Step 1 risk identified response <a class="govuk-link" href="https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Advice_from_CMDh/Nitrosamins/CMDh_407_2019_Rev.1_2021_01_-_Step_1_risk_identified_response_template.docx" rel="external">template document and spreadsheet</a></p>
  </li>
</ul>

<p>Completed template file names should begin with the relevant UK number i.e. PL, PLGB or PLNI as appropriate for easy identification and no documents should be scanned or locked. It must still be possible for accurate, automated, text copying to occur from the completed document.</p>

<p>For efficient processing please also provide a table with all submissions using the MHRA excel template below, ensuring the minimal requirements requested are fully completed for each product on separate rows. There is no requirement for a separate cover letter to be sent with the templates and no other spreadsheets will be required by the MHRA at Step 1. Bulks of up to 20 completed risk assessment forms with the same outcome will be accepted only if supported by tabulated details of the bulk submission in the template provided. Each bulk should be submitted as a separate submission. Please note the specific format requirements for the PL/PLGB/PLNI number - further examples are provided in the tips and examples for successful submissions document below.</p>

<p>Step 1 <a class="govuk-link" href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/872089/MHRA_Nitrosamine_Submission_-_Step_1.xlsx" rel="external">MHRA Excel Table template</a></p>

<p>For further guidance, please read these <a class="govuk-link" href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/884081/Tips_and_examples_for_successful_submissions.pdf" rel="external">tips and examples for successful submissions</a> before submission.</p>

<p>eCTD format should not be used and the MAH should submit the completed forms as information updates via <a class="govuk-link" href="https://www.gov.uk/guidance/registering-to-make-submissions-to-the-mhra-from-1-january-2021">MHRA Submissions</a> using the regulatory activity: Nitrosamine Step 1 – and sub-category: Response.</p>

<p>For EU licences where Northern Ireland is CMS, the completed forms should be submitted as information updates via CESP using the regulatory activity ID: G0008 - Follow-Up Measure and sub activity ID: H005 - Closing Documents.</p>

<p>The submission of the risk evaluation template as the outcome of Step 1 can take place only once.</p>

<ul>
  <li>If the Step 1 template is submitted with risk identified, it cannot be subsequently revised by a Step 1 re-submission. Confirmatory testing should commence immediately and a Step 2 submission should follow no later than the published deadline.</li>
  <li>If the template is submitted with no risk identified and a risk is subsequently identified, Step 1 should be resubmitted and confirmatory testing commenced immediately. Step 2 submission should follow no later than the published deadline.</li>
</ul>

<p>Any changes to the risk classification must be handled in the product life cycle by submission of an appropriate procedure supported by a cover letter and all supporting data.</p>

<p>Please note that for MAs for which “no risk” is identified in Step 1, the detailed risk evaluation documents should be introduced into the CTD sequence (in section 3.2.P.5.5 or 3.2.P.5.6 with cross-references in the dossier as required) by including them at the next regulatory opportunity (i.e. quality variation). These documents are included in the CTD for information only and will not be routinely assessed.</p>

<h3>Step 2 – Risk assessment and confirmatory testing</h3>

<p>Please refer to <a class="govuk-link" href="https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Advice_from_CMDh/Nitrosamins/CMDh_412_2019_Rev.15_2021_12_clean_-_PG_to_MAHs_on_nitrosamines.pdf" rel="external">CMDh practical guidance</a> for MAHs of nationally authorised products (incl. MRP/DCP) in relation to the Art. 5(3) Referral on Nitrosamines. 
For all products licensed in the UK, Great Britain and Northern Ireland (including EU licences where Northern Ireland is CMS) the MAH should submit the templates supplied by CMDh depending on the outcome of the confirmatory testing:</p>

<ul>
  <li>
    <p>Step 2 <a class="govuk-link" href="https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Advice_from_CMDh/Nitrosamins/CMDh_411_2019__2019_10_-_Step_2_no_nitrosamine_detected_template_for_response.docx" rel="external">no nitrosamine detected response template document</a></p>
  </li>
  <li>
    <p>Step 2 nitrosamine detected response template <a class="govuk-link" href="https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Advice_from_CMDh/Nitrosamins/CMDh_409_2019_Rev.3_2021_09_Step_2_Nitrosamine_detected_response_template.docx" rel="external">document</a></p>
  </li>
  <li>
    <p>Step 2 <a class="govuk-link" href="https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Advice_from_CMDh/Nitrosamins/CMDh_410_2019_Rev.1_2021_01-Step_2_-_Nitrosamine_detected_above_acceptable_intake_or_new_nitrosamine_detected_response_template.xlsx" rel="external">nitrosamines detected above acceptable intake or new nitrosamine detected response template</a></p>
  </li>
</ul>

<p>Submission Step 2 may be delayed beyond the deadline, for medicines that are not marketed on the due date, if no finished product batches are available for confirmatory testing. In such circumstances a Step 2, and if necessary, Step 3 submission must be submitted and approved before the product is placed on the market.</p>

<p>For national Marketing Authorisations where nitrosamines have been detected above the acceptable intake or where new nitrosamines have been detected, for efficient processing please also provide the following summary document which provides some additional guidance, a checklist of documents to be included in the submission and summary tables.</p>

<p><span class="attachment-inline"><a class="govuk-link" href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1021090/Step_2_summary_document_template_Clean_23-09-2021.docx">Summary document </a> (<span class="type">MS Word Document</span>, <span class="file-size">37 KB</span>)</span></p>

<p>eCTD format should not be used and the MAH should submit the completed documents:</p>

<ul>
  <li>
    <p>Existing MHRA Portal users should use the General Product Licensing Submission form</p>
  </li>
  <li>
    <p>via <a class="govuk-link" href="https://www.gov.uk/guidance/registering-to-make-submissions-to-the-mhra-from-1-january-2021">MHRA Submissions</a> using the regulatory activity: Nitrosamine Step 2 – and sub-category: Original Submission.</p>
  </li>
</ul>

<p>For EU licences where Northern Ireland is CMS, the completed documents should be submitted as information updates via CESP using the regulatory activity ID: G0053 – Summary Evaluation Reports and sub activity ID H0001 - Not applicable</p>

<p>Submissions may be bulked across different strengths of the same pharmaceutical form, provided their risk assessment outcome is identical.</p>

<h3>Step 3 - Changes to the marketing authorization</h3>

<p>Please refer to CMDh practical guidance for MAHs of nationally authorised products in relation to the Art. 5(3) Referral on Nitrosamines.</p>

<p>The necessary variation should be submitted through the usual channels by the above deadlines. It should be clearly identified in the reason comment that the change is the outcome of the Step 2 risk assessment and confirmatory testing.</p>
</div>

</div>

      <div class="responsive-bottom-margin">
        
<div class="app-c-published-dates app-c-published-dates--history govuk-!-margin-bottom-3" data-module="gem-toggle" lang="en">
    Published 18 December 2019
    <br>Last updated 11 August 2022
      <a class="app-c-published-dates__toggle govuk-link" data-controls="full-history" data-expanded="false" data-toggled-text="-&nbsp;hide all updates" href="#full-history">+&nbsp;show all updates</a>
      <div class="app-c-published-dates__change-history js-hidden">
        <ol class="app-c-published-dates__list">
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2022-08-11T09:02:59.000+01:00">11 August 2022</time>
              <p class="app-c-published-dates__change-note">Change to Step 3 timelines</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2022-03-15T14:41:30.000+00:00">15 March 2022</time>
              <p class="app-c-published-dates__change-note">3 links updates in the section "Step 2 – Risk assessment and confirmatory testing"</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2021-09-28T10:50:27.000+01:00">28 September 2021</time>
              <p class="app-c-published-dates__change-note">Added information about submission under section 'Step 2 – Risk assessment and confirmatory testing'.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2021-06-24T12:23:33.000+01:00">24 June 2021</time>
              <p class="app-c-published-dates__change-note">Updated information following the passing of the deadline for the submission of step 1 risk evaluation outcomes for medicines containing chemically synthesised API.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-12-31T23:01:42.000+00:00">31 December 2020</time>
              <p class="app-c-published-dates__change-note">Following the end of the transition period, added references to products licensed in UK, Great Britain and Northern Ireland.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-10-07T14:37:31.000+01:00">7 October 2020</time>
              <p class="app-c-published-dates__change-note">Updated step 2 submissions information</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-08-11T15:29:00.000+01:00">11 August 2020</time>
              <p class="app-c-published-dates__change-note">We have updated the step 1 response.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-05-11T12:18:54.000+01:00">11 May 2020</time>
              <p class="app-c-published-dates__change-note">Guidance in Article 5(3) and the Tips and examples for successful submissions has been updated.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-03-25T16:59:11.000+00:00">25 March 2020</time>
              <p class="app-c-published-dates__change-note">We have updated the deadline information due to the Coronavirus (COVID-19) outbreak</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-03-23T16:47:08.000+00:00">23 March 2020</time>
              <p class="app-c-published-dates__change-note">Added 'Customer Nudging Piece for Nitrosamine Submissions' document</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-03-12T10:25:35.000+00:00">12 March 2020</time>
              <p class="app-c-published-dates__change-note">Uploaded new MHRA Excel Table template.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2020-02-12T09:30:53.000+00:00">12 February 2020</time>
              <p class="app-c-published-dates__change-note">Updated information about formats to be used for submission and provided an Excel spreadsheet template.</p>
            </li>
            <li class="app-c-published-dates__change-item">
              <time class="app-c-published-dates__change-date timestamp" datetime="2019-12-18T15:08:00.000+00:00">18 December 2019</time>
              <p class="app-c-published-dates__change-note">First published.</p>
            </li>
        </ol>
      </div>
</div>

<div class="govuk-!-display-none-print govuk-!-margin-bottom-0" data-module="gem-track-click">
  <form action="/email/subscriptions/single-page/new" class="gem-c-single-page-notification-button" data-button-location="bottom" data-track-action="Subscribe-button-bottom" data-track-category="Single-page-notification-button" data-track-label="/guidance/medicines-marketing-authorisation-holders-submission-of-nitrosamine-risk-evaluation" method="POST">
    <input name="base_path" type="hidden" value="/guidance/medicines-marketing-authorisation-holders-submission-of-nitrosamine-risk-evaluation">
    <button class="govuk-body-s gem-c-single-page-notification-button__submit" type="submit">  <svg class="gem-c-single-page-notification-button__icon" height="18" viewBox="0 0 459.334 459.334" width="18" xmlns="http://www.w3.org/2000/svg"><path d="M177.216 404.514c-.001.12-.009.239-.009.359 0 30.078 24.383 54.461 54.461 54.461s54.461-24.383 54.461-54.461c0-.12-.008-.239-.009-.359H175.216zM403.549 336.438l-49.015-72.002v-89.83c0-60.581-43.144-111.079-100.381-122.459V24.485C254.152 10.963 243.19 0 229.667 0s-24.485 10.963-24.485 24.485v27.663c-57.237 11.381-100.381 61.879-100.381 122.459v89.83l-49.015 72.002a24.76 24.76 0 0 0 20.468 38.693H383.08a24.761 24.761 0 0 0 20.469-38.694z" fill="currentColor"></path></svg>Get emails about this page
</button>
</form>
</div>

      </div>

  </div>
    
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
  </div>
  
<div class="govuk-grid-column-one-third">
  


</div>

</div>

  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav class="gem-c-related-navigation__nav-section" data-module="gem-toggle" role="navigation">

    <h2 class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="gem-track-click">


        <li class="gem-c-related-navigation__link"><a class="govuk-link govuk-link gem-c-related-navigation__section-link govuk-link gem-c-related-navigation__section-link--footer" data-track-action="1.1 Explore the topic" data-track-category="relatedLinkClicked" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{&quot;dimension28&quot;:&quot;1&quot;,&quot;dimension29&quot;:&quot;Marketing authorisations, variations and licensing guidance&quot;}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>


    </main>